Related Experiment Video
Updated: May 22, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Targeting interleukin-4 in asthma: lost in translation?
Tania Maes1, Guy F Joos, Guy G Brusselle
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. tania.maes@ugent.be
American Journal of Respiratory Cell and Molecular Biology
|April 28, 2012
Summary
Targeting interleukin-4 (IL-4) shows promise for asthma treatment, but challenges remain. Further research into IL-4 and IL-13 pathways is needed for specific patient subsets.
Area of Science:
- Immunology
- Pulmonology
- Allergy
Background:
- Interleukin-4 (IL-4) identified as key in allergic airway inflammation since the 1990s.
- Early animal models suggested IL-4 targeting as an asthma cure, but clinical translation has been challenging.
- Biological overlap between IL-4 and IL-13 necessitates simultaneous blockade.
Purpose of the Study:
- To review the role of IL-4 in asthma pathogenesis.
- To describe IL-4 signaling pathways.
- To provide an overview of preclinical and clinical studies targeting the IL-4 Receptor pathway for asthma.
Main Methods:
- Review of existing literature on IL-4, IL-13, and asthma.
- Analysis of preclinical studies in animal models.
- Examination of clinical trial data from phase I/II studies.
Main Results:
- Targeting IL-4/IL-13 demonstrates potential clinical benefit in ongoing studies.
- Asthma is now understood to involve diverse phenotypes, not solely Th2-mediated.
- Specific targeting of Th2 cytokines like IL-4, IL-5, and IL-13 may benefit only certain patient groups.
Conclusions:
- IL-4, alongside IL-13, remains a critical target for asthma research.
- Understanding distinct asthma phenotypes is crucial for effective cytokine-targeted therapies.
- Further investigation into IL-4/IL-13 pathways and the IL-4 Receptor is warranted.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.